thalidomide has been researched along with Affective Disorders in 2 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide is a potent teratogen that causes dysmelia in humans." | 2.70 | A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. ( Chen, CC; Dahut, W; Dixon, S; Duray, P; Figg, WD; Floeter, MK; Gubish, E; Hamilton, M; Jones, E; Kohler, DR; Krüger, EA; Linehan, WM; Pluda, JM; Premkumar, A; Reed, E; Steinberg, SM; Tompkins, A, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Juliusson, G | 1 |
| Celsing, F | 1 |
| Turesson, I | 1 |
| Lenhoff, S | 1 |
| Adriansson, M | 1 |
| Malm, C | 1 |
| Figg, WD | 1 |
| Dahut, W | 1 |
| Duray, P | 1 |
| Hamilton, M | 1 |
| Tompkins, A | 1 |
| Steinberg, SM | 1 |
| Jones, E | 1 |
| Premkumar, A | 1 |
| Linehan, WM | 1 |
| Floeter, MK | 1 |
| Chen, CC | 1 |
| Dixon, S | 1 |
| Kohler, DR | 1 |
| Krüger, EA | 1 |
| Gubish, E | 1 |
| Pluda, JM | 1 |
| Reed, E | 1 |
1 trial available for thalidomide and Affective Disorders
| Article | Year |
|---|---|
A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer.
Topics: Aged; Aged, 80 and over; Androgens; Angiogenesis Inhibitors; Dose-Response Relationship, Drug; Endot | 2001 |
1 other study available for thalidomide and Affective Disorders
| Article | Year |
|---|---|
Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Bence Jones Protein; Drug Administration Schedule; Female; Hum | 2000 |